Previous Section
Guidebook Subsections
Introduction to Acute Myelogenous Leukemia
- Secondary AML
- Standard AML
Core-binding factor AML and APL are distinguished by their morphological appearance under the microscope (histology) and their chromosome abnormalities (cytogenetics). Secondary AML refers to AML developing after chemotherapy for a prior malignancy, for example breast cancer or a lymphoma such as Hodgkin's disease. As will be described below, different types of AML differ in prognosis and treatment. The core-binding factor leukemias and APL have the most favorable prognosis.
